Listed by the USPTO as OLSEN, KAELEIGH ELIZABETH
Tech Center 1600 • Art Units: 1619
This examiner grants 47% of resolved cases
OLSEN, KAELEIGH ELIZABETH has resolved 34 cases in Tech Center 1600 and Art Unit 1619. The allowance rate is 47.1%, the interview lift is 64.3%, and the median time to allowance is 1263 days. The interview lift exceeds the allowance rate, indicating that interviews are a prominent feature of the available record. Since the docket contains 34 resolved cases, practitioners should use the figures as guidance rather than as a definitive forecast.
The principal companies are L'Oréal, MannKind Corporation, and Max Co., Ltd. The leading firms are OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., BIRCH STEWART KOLASCH & BIRCH, LLP, and BUCHANAN, INGERSOLL & ROONEY PC. These affiliations add context for counsel evaluating prosecution in Art Unit 1619.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18265460 | MICROPARTICLE COMPOSITIONS COMPRISING FUNGICIDES | Final Rejection | BASF CORPORATION |
| 18558976 | COMPOSITIONS CONTAINING AT LEAST ONE BIOSURFACTANT AND AT LEAST ONE SULFONIC OR SULFINIC ACID DERIVATIVE | Non-Final OA | Evonik Operations Gmbh |
| 18290065 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ANIONIC SURFACTANT, ONE AMPHOTERIC OR ZWITTERIONIC SURFACTANT, ONE OIL-IN-WATER EMULSION AND ONE PARTICULAR AGENT | Final Rejection | L'OREAL |
| 18224125 | METHODS FOR REDUCING FRIZZ AND IMPROVING SMOOTHNESS OF HAIR | Final Rejection | L'OREAL |
| 17999220 | ANTI-ACNE COMPOSITIONS | Non-Final OA | L'OREAL |
| 17787526 | RETINOL-BASED SERUM | Non-Final OA | L'OREAL |
| 17787508 | RETINOL-BASED COMPOSITION | Non-Final OA | L'OREAL |
| 18289669 | RESHAPING COMPOSITION FOR KERATIN FIBERS | Non-Final OA | KAO GERMANY GMBH |
| 17788582 | OIL-IN-WATER-TYPE EMULSIFIED COSMETIC | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18005494 | HERBICIDAL COMPOSITION AND METHOD FOR CONTROLLING WEEDS | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18014044 | POLYETHER PHOSPHATE ESTER COMPOUNDS, COMPOSITIONS AND USES | Non-Final OA | Croda, Inc. |
| 17909342 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | Non-Final OA | SYMRISE AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy47.1% of resolved applications examined by Kaeleigh Elizabeth Olsen were allowed (34 resolved cases), compared with 22.7% across Art Unit 1619 over the last five years.
This examiner's interview lift is +64.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kaeleigh Elizabeth Olsen took 1,263 days on average from filing to allowance.
Kaeleigh Elizabeth Olsen examines applications in Art Unit 1619 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
